Lidocain Aguettant

Lidocaine, the active ingredient in Lidocain Aguettant, is a local anesthetic presented as a sterile solution for infiltration, intradermal and intravenous use. It provides reversible nerve block for minor surgical, dental and regional anesthesia procedures.

GNH USA supplies Lidocain Aguettant as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lidocaine is a local anesthetic used to block nerve conduction in various procedural settings.

Minor surgical procedures: provides local anesthesia to facilitate pain‑free incision and manipulation. Dental procedures: numbs oral tissues for extractions, restorations and other dental work. Infiltration anesthesia: delivers targeted anesthesia for soft‑tissue surgeries. Intradermal anesthesia: used for skin testing and minor dermatologic interventions. Intravenous regional anesthesia: enables a Bier block for limb surgeries.

Lidocaine may cause a range of adverse reactions, most of which are dose‑related and dependent on the route of administration.

Common Side Effects: - Tingling or numbness at the injection site - Burning or stinging sensation - Dizziness or light‑headedness - Nausea or metallic taste

Serious or Rare Side Effects: - Methemoglobinemia - Cardiac arrhythmias or conduction block - Seizures or central nervous system toxicity - Severe allergic reactions, including anaphylaxis - Hypotension or respiratory depression

When using Lidocain Aguettant, clinicians should observe several safety measures.

Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics. Cardiovascular status: use cautiously in patients with conduction disorders or severe heart disease. Dosage limits: adhere to recommended maximum doses to avoid systemic toxicity. Pregnancy and lactation: evaluate risk–benefit; limited data are available. Store at ambient temperature: keep in original container, protect from light and moisture.

Lidocaine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may potentiate cardiotoxicity. - Beta‑blockers and calcium channel blockers: increase risk of bradycardia and hypotension. - CYP3A4 inhibitors (e.g., ketoconazole): can raise plasma lidocaine levels. - Monoamine oxidase inhibitors: may enhance central nervous system toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs: may increase bleeding risk. - General anesthetics (e.g., propofol): additive CNS depression. - Diuretics (e.g., furosemide): may affect plasma protein binding.